The healthcare industry is undergoing one of the most significant transformations in its history. Digitalization, artificial intelligence, and data-driven decision-making are redefining how medical technologies are developed, approved, and monitored.  In this new landscape, regulatory consulting is no longer limited to managing submissions and compliance, it has become a strategic function that shapes how innovation reaches patients. The future belongs to consultancies that can connect technical expertise, business intelligence, and digital agility.  From Reactive Compliance to Predictive Strategy  Traditional regulatory consulting focused primarily on reacting to updates and managing documentation. The new era demands something more: anticipation.  Consultancies must now interpret regulatory trends, anticipate future requirements, and design strategies that align compliance with business growth. This approach transforms regulation into a predictive advantage, allowing manufacturers and distributors to prepare for changes before they happen.  At Brisa, this shift is already part of our DNA. Through continuous monitoring of regulatory updates and data analytics, we provide our clients with insights that shape long-term decisions, not just immediate approvals.  Technology as an Enabler  The future of regulatory consulting will be powered by technology and automation. Digital platforms are already transforming how submissions, quality documentation, and post-market data are managed. Artificial Intelligence (AI) is enabling faster classification, error detection, and real-time monitoring of compliance indicators.  However, technology alone is not the differentiator, how it is applied strategically is what sets leaders apart.  At Brisa, we combine AI-driven tools with human expertise, ensuring that every insight is interpreted within the right regulatory and business context. This balance of technology and judgment creates efficiency without losing precision.  Global Convergence and the Rise of Cross-Border Expertise  As regulatory frameworks around the world become increasingly harmonized, manufacturers seek partners capable of operating across multiple markets. The modern consultancy must understand not only local regulations, like those of Anvisa, but also the broader network of standards from the IMDRF, FDA, and EMA.  For Brisa, this global perspective is essential. We work with international manufacturers who view Brazil not only as a market, but as a strategic hub for Latin America, a region that values both technical rigor and partnership-based collaboration.  By bridging local expertise with global requirements, Brisa provides clients with a unified regulatory strategy that scales.  Human Expertise Remains at the Core  Even as automation grows, human expertise remains irreplaceable. The ability to interpret gray areas, communicate effectively with regulators, and design creative yet compliant solutions is still rooted in human insight and experience.  At Brisa, our consultants combine years of technical knowledge with a deep understanding of how regulation interacts with business models. This is what allows us to move beyond process execution and into strategic guidance.  Conclusion: The Consultancy of the Future  The regulatory consultancy of the future will not just ensure compliance, it will shape markets, accelerate innovation, and enable access to healthcare technologies.  At Brisa, we are building this future today. By integrating intelligence, technology, and human expertise, we turn regulatory complexity into strategic clarity.  Because the future of consulting is not about managing regulations, it’s about leading through them.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

In the medical device industry, trust is the foundation of every business relationship between regulators, manufacturers, healthcare providers, and ultimately, patients.  That trust is built through compliance and ethical conduct, two pillars that ensure safety, transparency, and credibility in an increasingly complex regulatory environment.  At Brisa, compliance is not just a procedural requirement; it is part of our identity and a cornerstone of how we operate across every stage of the regulatory and commercial journey.  The Meaning of Compliance in the Regulatory Context  Compliance goes beyond following rules  it represents a commitment to integrity and responsibility.  In the context of medical devices, compliance encompasses a broad range of obligations, including:  * Regulatory adherence: meeting all requirements established by Anvisa and international health authorities.  * Quality management: maintaining certified systems, such as ISO 13485 and Good Manufacturing Practices (CBPF).  * Traceability and documentation: ensuring that every product, process, and transaction can be verified transparently.  * Corporate governance: adopting policies that align with ethical standards and prevent conflicts of interest.  By embedding these principles into daily operations, companies demonstrate respect for both regulation and the people it protects.  Ethics as a Strategic Value  Ethics in healthcare regulation is more than compliance — it is about decision-making guided by values.  In a sector that directly affects human lives, ethical choices are essential to ensure that commercial objectives never override patient safety.  An ethical approach means:  * Communicating transparently with regulators and partners.  * Managing data, approvals, and reporting with honesty and accountability.  * Ensuring that all market practices are fair, traceable, and aligned with the public interest.  * At Brisa, ethics defines how we represent our clients, manage partnerships, and deliver value.  We believe that sustainable business growth comes only from integrity and long-term trust.  The Relationship Between Compliance, Risk, and Reputation  A strong compliance structure not only prevents penalties or delays  it protects corporate reputation and market longevity.  In the medical device industry, noncompliance can lead to product recalls, import suspensions, and reputational damage that takes years to rebuild.  Conversely, companies with mature compliance programs gain a competitive advantage:  – Faster approvals due to reliable documentation and transparency.  – Stronger relationships with regulators.  – Greater confidence from partners and healthcare institutions.  In a market increasingly guided by data and digital governance, integrity has become a measurable asset.  Brisa’s Commitment to Ethical Compliance  At Brisa, compliance is embedded into every process of our integrated ecosystem.  We maintain transparent workflows, continuous monitoring of regulatory updates, and rigorous internal governance to ensure that our operations  and those of our clients meet the highest ethical standards.  Our role is to connect global innovation to the Brazilian market responsibly, ensuring that every product reaching patients has passed through a chain of integrity and trust.  Conclusion: Ethics as the Future of Regulation  As healthcare regulation evolves, ethics and compliance are not just expectations — they are strategic imperatives.  They build the credibility that sustains innovation and the partnerships that make global collaboration possible.  At Brisa, we believe that compliance is not the end of the regulatory process  it is the beginning of a relationship built on trust, transparency, and purpose.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br    Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

From Compliance to Growth: The Power of an Integrated Regulatory Ecosystem  In the medical device industry, success is no longer defined solely by having an innovative product  it also depends on the ability to navigate complex regulatory, logistical, and commercial environments efficiently.  Traditional models, where each step of the process operates in isolation, often lead to fragmented communication, higher costs, and lost opportunities.  That is why Brisa has developed an integrated business model, designed to connect every part of the healthcare value chain  from regulatory approval to distribution  ensuring transparency, agility, and sustainable growth.  Why Integration Matters  – Medical device companies entering the Brazilian market face a unique combination of challenges:  – A rigorous regulatory framework (Anvisa)  – Complex import and taxation systems  – Regionalized distribution networks  – High expectations for traceability and post-market compliance  When these stages are managed separately, inefficiencies multiply.  An integrated approach, however, allows each component to work in synergy  where regulatory, operational, and commercial decisions are aligned from the start.  This approach transforms compliance into a strategic enabler, rather than an obstacle.  Brisa’s Integrated Model: A 360° View  At Brisa, we connect all the key elements of market access within a single, cohesive structure.  Our integrated model includes:  – Regulatory Consulting and Strategy  – Comprehensive support for Anvisa registration, CBPF certification, and compliance management.  – Proactive monitoring of regulatory changes to ensure readiness and agility.  – Legal Representation and Importation  – Acting as the local representative for foreign manufacturers.  – Managing import operations with optimized tax and logistics planning.  – Strategic Distribution Network  – Connecting manufacturers to trusted distributors, purchasing groups, and healthcare providers.  – Facilitating commercial expansion through a transparent and compliant framework.  – Post-Market and Vigilance Management  – Continuous tracking of product performance and technical complaints.  – Maintaining traceability and quality assurance throughout the lifecycle.  By combining these elements under one structure, Brisa ensures that information flows seamlessly, reducing risks, time to market, and operational costs.  Creating Value Across the Chain  An integrated model creates tangible value for all stakeholders:  – Manufacturers gain predictability, control, and faster access to the market.  – Distributors expand portfolios with compliant and high-quality technologies.  – Healthcare providers benefit from safer, faster access to innovative solutions.  – Patients ultimately gain from improved availability and reliability of medical technologies.  Through collaboration and shared intelligence, Brisa’s ecosystem strengthens the entire healthcare chain.  Sustainability Through Transparency and Governance  Integration also means strong governance.  Every process within the Brisa ecosystem is guided by transparency, traceability, and ethical standards.  By maintaining unified oversight, we ensure that manufacturers and partners operate with full compliance and confidence.  This model not only streamlines market entry  it builds long-term sustainability.  Conclusion: Integration as a Competitive Advantage  In today’s healthcare environment, the companies that thrive are those that see regulation, logistics, and commercialization as interconnected components of one ecosystem.  At Brisa, we turn this vision into reality combining expertise, technology, and collaboration to deliver results that go beyond regulatory approval.  Because when every link in the chain works together, the entire market moves forward.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

With one of the largest healthcare markets in the world and a highly structured regulatory framework, Brazil stands as the main gateway to Latin America for medical device manufacturers.  The country represents nearly 40% of the region’s medical device market, serving as both a key consumer base and an operational hub for regional expansion.  But what makes Brazil such a strategic point of entry is not only its size: it’s the combination of regulatory maturity, market sophistication, and growing demand for healthcare innovation.  A Market of Scale and Opportunity  Brazil’s healthcare sector is unique in its scale and diversity.  The country has more than 7,000 hospitals, a robust private sector, and a universal public health system (SUS) that provides care for approximately 70% of the population.  This ecosystem drives a continuous need for diagnostic, therapeutic, and monitoring technologies, creating opportunities for global manufacturers in areas ranging from hospital infrastructure to digital health and home care devices.  Moreover, Brazil’s healthcare expenditure accounts for around 9% of GDP, placing it among the top global markets for medical technology investment.  A Mature and Predictable Regulatory Environment  Brazil’s regulatory authority, Anvisa, is recognized as one of the most advanced in Latin America.  Its frameworks, harmonized with international standards such as those of the IMDRF and the World Health Organization (WHO), provide a solid base for manufacturers to operate with clarity, traceability, and long-term predictability.  Recent updates, such as RDC 751/2022, have modernized the classification and registration of medical devices, aligning Brazil’s system more closely with that of the European Union and the United States.  This alignment simplifies global compliance and reduces redundancies for companies already operating in highly regulated markets.  From Local Compliance to Regional Expansion  Many international manufacturers choose Brazil not only for its domestic potential but as a strategic hub for entry into other Latin American markets such as Chile, Colombia, Peru, and Argentina.  Once a company establishes local representation, obtains registration with Anvisa, and aligns its operations with Brazilian Good Manufacturing Practice (CBPF) certification, it gains a significant advantage for regional harmonization and mutual recognition.  In this way, Brazil becomes more than a market: it becomes a platform for regional growth.  Brisa’s Role in Connecting Global Innovation to Latin America  At Brisa, we specialize in helping international manufacturers navigate the Brazilian regulatory landscape and expand strategically across Latin America.  Through our integrated ecosystem, combining regulatory consulting, importation, legal representation, and distribution, we turn compliance into a seamless process that accelerates market entry.  Our expertise allows clients to transition from regulatory complexity to commercial opportunity, ensuring that innovation reaches healthcare providers and patients efficiently and sustainably.  Conclusion: A Market that Leads and Connects  Brazil’s size, regulatory maturity, and growing healthcare demand position it as Latin America’s natural gateway for medical technology.  For manufacturers looking to expand in the region, investing in a structured and compliant operation in Brazil is not just an entry point: it’s a strategic move for long-term growth.  At Brisa, we help global innovators take that step with confidence, connecting regulation, business, and access across borders.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

Adapting to Change: How New Regulatory Frameworks Are Shaping the Brazilian Medical Device Market  Regulatory evolution is constant in healthcare, and in Brazil, recent updates from Anvisa have significantly reshaped how manufacturers, distributors, and importers operate.  From product registration to post-market monitoring, these changes are driving greater transparency, predictability, and alignment with global best practices.  For companies in the medical device sector, staying ahead of regulatory change is no longer optional: it’s a strategic necessity.  A Move Toward International Harmonization  In the past few years, Anvisa has intensified efforts to harmonize its regulations with international frameworks such as the IMDRF (International Medical Device Regulators Forum), the WHO, and the Pan American Health Organization (PAHO).  This alignment facilitates international cooperation, simplifies documentation for multinational manufacturers, and strengthens Brazil’s credibility as a regulatory reference in Latin America.  One major milestone was the publication of RDC 751/2022, which restructured the classification, registration, and labeling requirements for medical devices, replacing the former RDC 185/2001.  The new resolution clarifies risk criteria, updates terminology, and introduces more efficient mechanisms for digital submission.  Key Areas of Regulatory Modernization  Recent updates reflect Anvisa’s focus on modernization, transparency, and digital efficiency. Among the highlights are:  Digital transformation of submissions: The move toward electronic petitions and online systems has reduced bureaucracy and improved traceability of processes.  Risk-based regulatory approach: By calibrating requirements according to product risk, Anvisa allows faster approval for low-risk devices while maintaining rigorous evaluation for high-risk technologies.  Good Manufacturing Practice (GMP/CBPF) improvements: Updated inspection and certification procedures now prioritize companies with consistent quality systems, improving oversight while reducing bottlenecks.  Post-market surveillance reinforcement: The agency has expanded obligations for adverse event reporting and implemented new channels for transparency, improving patient safety and data integrity.  Together, these updates reflect a broader shift: from procedural control to outcome-based regulation, focused on product quality, reliability, and real-world performance.  How These Changes Affect Market Access  For manufacturers, the new regulatory environment brings both challenges and opportunities.  Companies that adapt quickly to Anvisa’s updated frameworks gain a competitive advantage: faster approvals, greater operational predictability, and stronger market trust.  Those that delay adaptation, however, risk compliance gaps and longer approval timelines.  In a market as dynamic as Brazil, regulatory readiness has become a decisive factor in business success.  Brisa’s Role: Turning Regulation into Strategy  At Brisa, we continuously monitor regulatory changes, analyze their implications, and translate them into actionable strategies for our clients.  Our team supports manufacturers and distributors in updating documentation, redefining internal procedures, and aligning global compliance standards with Brazilian requirements.  By combining regulatory intelligence, technical expertise, and local insight, we ensure that adaptation becomes an opportunity, not a challenge.  Conclusion: Evolving with the Market  The modernization of Brazil’s regulatory landscape reflects a commitment to safety, innovation, and global alignment.  For the medical device industry, it signals a new era of efficiency, transparency, and strategic partnership with regulators.  At Brisa, we help our clients evolve with this transformation, ensuring that each update becomes a step toward greater competitiveness and sustainable growth.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

For every medical device entering the Brazilian market, classification is the first and most critical regulatory step. This process determines not only how the device will be evaluated by Anvisa (Brazil’s National Health Surveillance Agency) but also the scope, cost, and timeline of its approval.  In other words, accurate classification is the foundation of an efficient regulatory strategy. Misclassification, on the other hand, can lead to delays, noncompliance, or even market withdrawal.  The Logic Behind Classification  Anvisa’s classification framework follows international standards harmonized with the International Medical Device Regulators Forum (IMDRF). It is based on the principle of risk management: the higher the potential risk to the patient or user, the stricter the regulatory requirements.  Each device is classified into one of four risk classes:  This classification defines whether the device will go through a notification (cadastro) or a registration (registro) process, as well as whether Good Manufacturing Practice (CBPF) certification will be required.  Key Criteria Considered by Anvisa  When determining the risk class, Anvisa evaluates a combination of technical and clinical factors, including:  These parameters must be carefully documented and justified in the technical dossier. A well-structured rationale can make the difference between a smooth submission and one that requires multiple rounds of clarification.  Why Proper Classification Is Strategic  Correct classification goes beyond regulatory compliance; it is a strategic decision. It directly influences:  By defining the right path early, manufacturers can plan production, importation, and commercialization with far greater predictability.  Brisa’s Expertise in Classification and Regulatory Strategy  At Brisa, we support manufacturers and distributors in accurately classifying their products and designing the most efficient regulatory pathway for entry into Brazil. Our team analyzes each device from a technical, legal, and clinical perspective, ensuring full alignment with Anvisa’s expectations and IMDRF standards.  Through our integrated regulatory ecosystem, we combine classification, registration, importation, and commercialization under a unified strategy, enabling our clients to bring innovation to the market safely and efficiently.  Conclusion: Every Successful Approval Starts with the Right Classification  In a market as dynamic and demanding as healthcare, success begins with precision. A clear understanding of classification not only ensures compliance but also accelerates innovation, protects patients, and strengthens trust.  At Brisa, we help global manufacturers navigate this first and most decisive step because every successful regulatory journey starts with the right classification.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

In the highly regulated healthcare environment, making decisions without updated data and strategic analysis is a risk no company can afford.That’s why regulatory intelligence has become a fundamental pillar for any organization operating in the medical device market, especially in Brazil, where the regulatory framework is complex, detailed, and constantly evolving. More than just following Anvisa’s publications, regulatory intelligence means anticipating scenarios, interpreting trends, and turning information into strategy. What Is Regulatory Intelligence Regulatory intelligence is the systematic process of collecting, analyzing, and applying information related to regulatory frameworks, public policies, technical standards, and market practices. Its purpose is to predict risks, identify opportunities, and support decision-making based on concrete data. In practice, this means continuously monitoring: Updates from Anvisa and other health authorities;Changes in resolutions and normative instructions (RDCs and INs);International harmonization movements (IMDRF, WHO, PAHO);Market trends that may affect the approval, importation, or commercialization of medical products. Why Regulatory Intelligence Is Strategic Companies that apply regulatory intelligence gain both agility and security.Instead of reacting to changes, they anticipate them, adjusting their products, documentation, and internal processes proactively. The key benefits include: Risk reduction, preventing delays, sanctions, and rework;Operational efficiency, focusing resources on what truly matters;Faster approvals, adapting early to new requirements;Competitiveness, turning compliance into a market advantage. In complex markets such as Brazil, where regulations are detailed and frequently updated, regulatory intelligence is what separates companies that merely operate from those that lead with strategy. Brisa’s Role in Regulatory Intelligence At Brisa, regulatory intelligence is at the core of our approach.We continuously monitor regulatory updates, public consultations, and international trends to translate information into strategic direction for our clients. Our specialists combine technical analysis, legal knowledge, and business insight to develop customized regulatory plans that align innovation, compliance, and commercial viability. This integrated approach enables manufacturers and distributors to make informed, predictable decisions in a challenging regulatory environment. Conclusion: Data, Strategy, and Regulation Move Together In a sector undergoing constant transformation, information is the most valuable asset for sustainable growth.Regulatory intelligence is not just a monitoring tool, it is a competitive advantage capable of transforming regulation into a driver of growth. At Brisa, we believe that anticipating regulatory change is just as important as innovating in technology, and that is why regulatory intelligence stands at the heart of our ecosystem. Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

In the medical device industry, no one grows alone.  Regulatory complexity, tax burden, and logistical challenges make it essential to establish strategic partnerships among manufacturers, distributors, consultancies, and local operators.  More than a trend, this integration has become a key driver of competitiveness and sustainability.  At Brisa, we believe that strong partnerships are the link connecting innovation, regulation, and access.  An industry that depends on synergy  The healthcare sector is made up of an extensive chain, from technology development to clinical use, and every link must operate in synergy to ensure safety and efficiency.  Manufacturers, distributors, and service providers work in a highly regulated environment, and collaboration among them is what ensures that innovation reaches the market sustainably.  Strategic partnerships make it possible to eliminate redundancies, optimize processes, and share regulatory intelligence, leading to greater predictability and reduced costs.  Partnerships that expand access and reduce barriers  For international manufacturers, Brazil represents a promising but technically demanding market.  In this context, partnering with specialized consultancies and experienced local operators is the most effective way to overcome entry barriers and ensure compliance with Anvisa’s requirements.  An experienced partner provides not only operational support, but also strategic insight into taxation, logistics, regulation, and market positioning.  When well structured, such collaboration transforms regulatory challenges into a true competitive advantage, especially in the context of MDSAP and GMP good practices.  Integration and transparency as pillars  The ideal partnership model is built on integration and transparency.  Each participant understands its role in the product lifecycle and acts with a shared commitment to sustainable results.  At Brisa, we work through a collaborative approach, connecting manufacturers, distributors, and purchasing groups within an integrated regulatory ecosystem that enables data sharing, timeline optimization, and coordinated market access strategies.  This model is especially relevant for companies seeking FDA registration and needing to navigate simultaneously through Brazilian and North American regulatory systems.  The Brisa ecosystem as a model of collaboration  The Brisa ecosystem was designed to bring together all players in the healthcare chain around a common goal: facilitating access to innovative medical technologies in Brazil.  Our model combines:  Specialized regulatory consulting: ensuring the safe and efficient entry of products, including support for medical device consulting and compliance with Anvisa standards.  Importation and legal representation: with optimized fiscal and logistical structures, facilitating contact Anvisa and processes with authorities such as the Medical Device Authority and Health Sciences Authority.  A strategic distribution network: linking manufacturers to regional buyers and healthcare institutions.  Comprehensive governance and traceability: ensuring compliance at every stage, including UDI requirements and product identification systems.  This collaborative format reduces costs, shortens timelines, and expands access to essential medical technologies, benefiting manufacturers, distributors, and Brazil’s healthcare system as a whole.  Conclusion: collaboration as a driver of innovation  Today, healthcare innovation depends not only on technology, but on the quality of the partnerships that support it.  Building strategic alliances based on trust, transparency, and shared objectives is what turns projects into measurable results.  At Brisa, we believe the future of healthcare is collaborative, integrated, and sustainable, which is why partnerships are at the heart of our ecosystem.  For companies seeking to better understand the Brazilian regulatory framework and optimize their market entry strategies, having partners who master everything from RDCs to international requirements of Health Products Regulatory Authority and Medical Products Agency makes all the difference.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

Bringing a medical technology into Brazil involves much more than logistics and commercialization.Behind every device lies a complex and essential regulatory chain, designed to ensure that products reach healthcare professionals, and ultimately patients, with safety, effectiveness, and full traceability. This journey, which begins with the manufacturer and ends at the clinical application, is carefully structured and supervised by Anvisa, Brazil’s National Health Surveillance Agency. Understanding each stage of this process is the first step toward operating successfully and sustainably in the Brazilian market. The regulatory journey begins at the product development stage, often in the country of origin.At this point, manufacturers perform performance tests, safety validations, and clinical evaluations (when applicable) to demonstrate compliance with international standards such as ISO 13485 and IMDRF guidelines.These documents form the foundation of the regulatory dossier that will later be submitted to Anvisa.The stronger this technical foundation, the more predictable and efficient the approval process becomes. To apply for registration, the manufacturer must appoint a legal representative in Brazil, responsible for managing the process with Anvisa and maintaining post-approval compliance.This representative acts as the key communication link between the manufacturer, the regulatory authorities, and local stakeholders. At Brisa, this function is embedded within an integrated ecosystem that combines legal representation, importation, and regulatory intelligence by giving manufacturers full governance and transparency over their products. The first official step in the regulatory process is the risk classification of the medical device, in accordance with RDC 751/2022.Based on this classification, the product will follow one of two regulatory pathways: Notification – for Class I and II devices, considered low or medium risk. This streamlined process focuses on documentary evidence, labeling, and quality system certification. Registration – for Class III and IV devices, considered high or maximum risk. This pathway requires a comprehensive technical dossier, including clinical data (when applicable), risk analysis, and proof of Good Manufacturing Practice (GMP) certification. Upon approval, the product receives a unique registration number, authorizing its importation, distribution, and commercialization throughout Brazil. Once registered, each product must undergo import authorization and sanitary clearance through Anvisa and the Brazilian Federal Revenue Service.This stage ensures that every imported batch maintains full traceability, integrity, and compliance with the approved regulatory conditions. Here, the integration between regulatory consulting and logistics operations becomes crucial and represents one of Brisa’s core differentiators. After clearance, the product enters the distribution phase, governed by RDC 665/2022, which establishes strict requirements for storage, transportation, and traceability.Every unit must be traceable back to its origin, ensuring that any nonconformity can be rapidly identified and resolved. Organizations that manage this phase efficiently deliver not only compliance but also market credibility and patient safety. The final stage of the journey occurs in the clinical setting, where the device is used by healthcare professionals.Even after market entry, regulatory obligations continue: the registration holder must monitor adverse events, handle technical complaints, and periodically update product documentation. This ongoing surveillance ensures that the device maintains its safety and performance throughout its entire lifecycle. A Journey that Demands Strategy Each stage of the regulatory process, from design to clinical use, requires planning, technical expertise, and integrated management.Companies that view regulation as part of their innovation strategy can reduce time to market, optimize costs, and accelerate patient access to new technologies. At Brisa, we’ve structured our regulatory ecosystem to accompany this complete journey, ensuring that every product moves from manufacturer to patient with efficiency, compliance, and trust. Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

New regulatory roadmap defines 161 priority themes for medical devices, pharmaceuticals, and health products  Key Highlights  The Brazilian Health Regulatory Agency (Anvisa Brasília) approved its Regulatory Agenda for 2026-2027 on December 10, 2024, establishing a comprehensive framework of 161 priority regulatory themes for the next two years.  Agenda Composition  Priority Distribution  Unprecedented Public Participation  The consultation process achieved record engagement:  Impact on Medical Device Sector  Companies engaged in medical device consulting should prepare for regulatory updates in:  Post-market surveillance enhancement  Implementation Timeline  Formal publication: Decree in Diário Oficial da União   Effective date: January 1, 2026  Monitoring tools: Daily and quarterly tracking panels available  Strategic Recommendations  Organizations should:  Conclusion  The 2026-2027 Regulatory Agenda represents a significant milestone for Brazilian healthcare regulation. With strong emphasis on medical devices, pharmaceuticals, and cross-sector harmonization, companies must begin strategic planning now to ensure compliance readiness by January 2026.  The unprecedented level of public participation  647 submissions generating over 2,000 manifestations  demonstrates the maturity of Brazil’s regulatory system and the importance of stakeholder engagement in shaping health policy.  Note: The complete translated list of themes is available at Anvisa’s official portal. / English Version   This article provides informational guidance and does not replace consultation with qualified regulatory professionals or official regulatory documents.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br